ETON Key Statistics, Chart & Performance
The current stock price of ETON is 16.57 USD. In the past month the price increased by 1.91%. In the past year, price increased by 23.29%.
ETON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.39 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.73 | 493.40B | ||
| MRK | MERCK & CO. INC. | 12.36 | 270.22B | ||
| PFE | PFIZER INC | 7.95 | 144.59B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.3 | 110.79B | ||
| ZTS | ZOETIS INC | 20.4 | 57.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.89 | 23.46B | ||
| VTRS | VIATRIS INC | 5.32 | 14.28B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.79 | 11.83B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.59B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About ETON
Company Profile
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 31 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Company Info
ETON PHARMACEUTICALS INC
21925 W Field Pkwy Ste 235
Deer Park ILLINOIS 60010 US
CEO: Sean E. Brynjelsen
Employees: 31
Phone: 18477877361
ETON PHARMACEUTICALS INC / ETON FAQ
What does ETON do?
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 31 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Can you provide the latest stock price for ETON PHARMACEUTICALS INC?
The current stock price of ETON is 16.57 USD. The price decreased by -0.96% in the last trading session.
Does ETON stock pay dividends?
ETON does not pay a dividend.
What is the ChartMill rating of ETON PHARMACEUTICALS INC stock?
ETON has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists ETON stock?
ETON stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of ETON PHARMACEUTICALS INC (ETON)?
ETON PHARMACEUTICALS INC (ETON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
ETON Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ETON. When comparing the yearly performance of all stocks, ETON turns out to be only a medium performer in the overall market: it outperformed 49.05% of all stocks.
ETON Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ETON. ETON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ETON Financial Highlights
Over the last trailing twelve months ETON reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 42.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -6.39% | ||
| ROE | -28.89% | ||
| Debt/Equity | 1.31 |
ETON Forecast & Estimates
9 analysts have analysed ETON and the average price target is 30.6 USD. This implies a price increase of 84.67% is expected in the next year compared to the current price of 16.57.
For the next year, analysts expect an EPS growth of 19.86% and a revenue growth 109.09% for ETON